Trial Profile
Impact of Rifaximin on Liver Fibrosis in HIV-Infected Patients With Liver Disease
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Rifaximin (Primary)
- Indications Hepatic encephalopathy; Hepatic fibrosis; Liver cirrhosis
- Focus Therapeutic Use
- 13 Jul 2018 According to a Bausch Health Companies media release, Valeant Pharmaceuticals International changed its name to Bausch Health Companies.
- 25 Sep 2015 Planned End Date changed from 1 Sep 2013 to 1 Sep 2015 as reported by ClinicalTrials.gov.
- 25 Sep 2015 Status changed from recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov.